Project Grant R01AI192398
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Brigham & Women's Hospital Inc. a Project Grant totaling $2,472,443 under the Allergy and Infectious Diseases Research program (CFDA 93.855) beginning June 1, 2026, with completion targeted for April 30, 2031. This research initiative investigates neutrophil heterogeneity in immune regulation through multiple integrated projects led by principal investigators examining distinct neutrophil...
- Federal Grant Award Summary Brigham & Women's Hospital Inc. received a $3.0M Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded June 17, 2026, with performance through May 31, 2030. This research initiative investigates somatic hypermutation (SHM) and antibody affinity maturation, specifically exploring the hypothesis that SHM can generate novel antibody specificities in B...
- Federal Grant Award Summary Brigham & Women's Hospital Inc. received a $855,342 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective June 12, 2026, with a completion date of May 31, 2031. The award supports investigator-initiated biomedical research examining the pathogenic roles of follicular helper T (Tfh) cells in systemic lupus erythematosus (SLE), a prototypical...
- Federal Grant Award Summary Brigham & Women's Hospital Inc. received a $3.08M Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded February 5, 2026, with completion targeted for January 31, 2030. This research initiative investigates the mechanisms sustaining pathogenic TH2 (Type 2 T helper cell) multipotent progenitor populations in chronic type 2 inflammatory diseases,...
- Federal Grant Award Summary Brigham & Women's Hospital Inc. (Department of Faulkner Pathology) received a $193,600 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective April 1, 2026 through March 31, 2031. The award funds investigator-initiated biomedical research to define the T cell state that sustains chronic allergic disease, with emphasis on understanding the...
- Federal Grant Award Summary Brigham and Women's Hospital, through its Department of Faulkner Pathology, received a $199,000 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective June 12, 2026 through May 31, 2031. This award supports investigator-initiated biomedical research examining the role of lung T follicular helper (TFH) cell subsets in airway-localized immunoglobulin E (IgE)...
- FEDERAL PROJECT GRANT AWARD SUMMARY The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $188,916 Project Grant to Brigham & Women's Hospital Inc. (Department of Faulkner Pathology) under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 1, 2025, with a completion date of July 31, 2030. This research project investigates how noncytotoxic Staphylococcus aureus evades detection and clearance by the innate immune system, with particular...
- Federal Project Grant Award Summary Brigham & Women's Hospital Inc., Department of Faulkner Pathology, received a $194,400 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 15, 2025, with completion targeted for August 31, 2029. The award supports research examining vaccine immunogenicity and adoptive transfer of immunity in allogeneic hematopoietic stem cell...
- Federal Grant Award Summary Brigham & Women's Hospital Inc. received a $879,282 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective June 1, 2026, through May 31, 2031. This award supports research to characterize novel receptors for Epstein-Barr Virus (EBV) epithelial cell entry, with the ultimate objective of identifying potential therapeutic targets to prevent EBV-associated...
- Federal Grant Award Summary Brigham & Women's Hospital Inc., operating through its Department of Faulkner Pathology in Boston, MA, received a $194,400 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded September 12, 2025, with completion targeted for August 31, 2030. This five-year research career development award supports a comprehensive investigation of antibody-dependent...
Brigham & Women's Hospital Inc., through the Department of Faulkner Pathology, received a $778,143 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) awarded June 3, 2026, with a completion date of May 31, 2031. This five-year research initiative investigates the regulation of naive follicular B cell polyreactivity and how antibody-producing B cells maintain diversity while preventing autoimmune responses. The research examines how microbial symbionts influence the composition of the B cell receptor (BCR) repertoire and the mechanisms by which tolerance checkpoints filter polyreactive antibodies during B cell maturation. The project delivers fundamental biomedical research through two specific aims: characterizing the influence of microbial symbionts on polyreactivity and antigen recognition capacity, and defining the contribution of the IL-17-neutrophil-BAFF (B-cell activating factor) axis in regulating microbial-mediated polyreactivity. The research is designed to elucidate how the immune system balances the protective benefits of antibody diversity against multiple pathogenic threats while simultaneously preventing self-reactive antibodies that could cause autoimmune disease. This investigator-initiated research contributes to the National Institutes of Health's broader mission to establish and expand biomedical research addressing infectious diseases and immunologic disorders.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $778.1k | 6/5/26 |